Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis

Launched by INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE GIRONA DR. JOSEP TRUETA · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how fat tissue and the bacteria in our gut may affect our brain function and thinking abilities, especially in people with obesity. Researchers have noticed that changes in fat tissue can impact memory and other brain activities in animals. They want to find out if similar effects occur in humans, and if understanding these connections can help predict changes in brain health over time. The study involves analyzing samples of fat tissue, blood, and gut bacteria to explore these relationships and possibly discover new ways to diagnose and treat cognitive issues related to obesity.

To participate in this study, you need to be at least 20 years old and scheduled for a surgery to remove some fat tissue. It’s important that you do not have certain health conditions, such as severe infections, major psychiatric issues, or chronic diseases that could interfere with the study. If you join, you can expect to provide samples for analysis and be part of a research effort that could lead to better understanding and management of cognitive problems in people with obesity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women \>20 years old.
• • Scheduled for surgical intervention to extract adipose tissue.
• • Signed informed consent for study participation.
• Exclusion Criteria:
• • Not meeting inclusion criteria.
• • Non-obesity-related systemic diseases (cancer, severe kidney/liver disease).
• • Systemic diseases with intrinsic inflammation (rheumatoid arthritis, Crohn's disease, asthma, chronic infections (HIV/tuberculosis)) or any type of infectious disease.
• • Pregnant/breastfeeding women.
• • Persons under legal/administrative restrictions.
• • Those with infection symptoms in the past month.
• • Use of antibiotics/antifungals/antivirals (previous 3 months).
• • Chronic steroidal/anti-inflammatory drug use.
• • Major psychiatric history.
• • Excessive alcohol intake, acute or chronic (\>40g/day (women), \>80g/day (men)) or drug abuse.
• • Immunosuppressants treatment.
• • Participants with severe eating disorders.
• • Serum liver enzymes (GOT, GPT) above twice the upper limit of normal. Obvious signs or symptoms of liver disease, acute or chronic hepatitis.
• • History of iron balance disorders (e.g., genetic hemochromatosis, hemosiderosis from any cause, atransferrinemia, paroxysmal nocturnal hemoglobinuria).
• • Creatinine greater than 1.2 and glomerular filtration rate below 40.
• • Current treatment for malignant neoplasia, other than basal cell or squamous cell skin cancer.
• • Heart disease classified as class III or IV, known ischemic cardiovascular disease.
• • Renal failure, history of kidney transplant, or current dialysis treatment.
• • Chronic constipation (bowel movement frequency ≥ 7 days) .